Acute Respiratory Infection Clinical Trial
— EMIRATHOfficial title:
Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims
NCT number | NCT02868541 |
Other study ID # | 2013-29 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 25, 2017 |
Est. completion date | September 6, 2019 |
Verified date | October 2022 |
Source | Assistance Publique Hopitaux De Marseille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this project is to study the prevalence of viruses and bacteria responsible for transmissible acute respiratory infections in the respiratory tract of pilgrims returning from the trip. The patients included, will be the consultant pilgrims to the traveler health center, and before leaving for Hajj. Based on the results obtained in previous studies, it is estimated that 200 pilgrims will be included each year, 600 in total (inclusion period of 3 years). Respiratory secretions are then collected by nasal swab and throat (swab) prior to departure for the hajj. In return, patients will be reconvened systematic consultation to record medical events potentially encountered during the trip, and it will again be performed the same nasal swabs and throat. It will then be performed on these samples' return from hajj "molecular detection (PCR and RT-PCR) of 35 viruses and bacteria respiratory tropism: influenza (3), RSV (2), metapneumovirus (1), Coronavirus (4), Parainfluenzavirus (4), enteroviruses (4), rhinovirus (1), adenovirus (6) bocavirus, polyomavirus (2), pneumococcus, Bordetella pertussis, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Coxiella burnetii. Samples "return of hajj" positive should be cultured for the isolation of the strain. For patients positive return, it will be done further research of these 35 viruses and bacteria on samples "start of hajj," the same method described above. In addition to this systematic consultation, and if symptoms return, the pilgrims will be seen in consultation for a diagnosis evaluation and therapeutic management. This study will shed light on the acquisition of microorganisms respiratory tropism during the stay and on the potential risks associated with the circulation of these pathogens after the trip.
Status | Completed |
Enrollment | 905 |
Est. completion date | September 6, 2019 |
Est. primary completion date | September 6, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All travelers presenting during the study period in the service of international vaccination for mandatory meningococcal ACYW135 vaccination , - Affiliated to a social security insurance regime - Male or Female - Aged over 18 years - Having signed informed consent form - able to understand and answer the study questions Exclusion Criteria - Patients aged under 18 - Patient whose protocol compliance seems unlikely to investigator - Participant in another clinical trial or in exclusion period of a previous clinical trial, - Unable to understand the nature and objectives of the study, - Refusing to sign the informed consent form. |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Hopitaux de Marseille | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of new viruses and/or bacteria identified and characterized by respiratory and pharyngeal carriage among pilgrims between the departure and the return of Hajj | up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03943654 -
Improving Nighttime Access to Care and Treatment (Part 2)
|
||
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Not yet recruiting |
NCT05902702 -
Isotonic Saline for Children With Bronchiolitis
|
N/A | |
Not yet recruiting |
NCT04525118 -
Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
|
||
Completed |
NCT01431469 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil
|
N/A | |
Completed |
NCT00981513 -
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
|
Phase 4 | |
Recruiting |
NCT06183229 -
Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
|
Phase 3 | |
Completed |
NCT03274310 -
FluSAFE: Flu SMS Alerts to Freeze Exposure
|
N/A | |
Completed |
NCT03736096 -
Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
|
||
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT03028077 -
Effects of GS-3K8 and GINst15 on Acute Respiratory Illness
|
N/A | |
Enrolling by invitation |
NCT01286285 -
Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria
|
N/A | |
Completed |
NCT03840135 -
Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
|
Phase 3 | |
Completed |
NCT01488435 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age
|
N/A | |
Not yet recruiting |
NCT00545961 -
Middle Meatal Bacteriology During Acute Respiratory Infection in Children
|
Phase 4 | |
Completed |
NCT05273619 -
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
|
Phase 3 | |
Recruiting |
NCT04415827 -
Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases
|
N/A | |
Completed |
NCT03459391 -
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT04938323 -
Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly
|
Phase 2/Phase 3 |